Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)

The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy.

FDA provides grants for clinical studies on safety


and/or effectiveness that will either result in, or substantially contribute to, market approval of these products.

Applicants must include in the application's Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a “rare disease or condition” and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

Related Programs

Food and Drug Administration_Research

Department of Health and Human Services


Agency: Food and Drug Administration

Office:

Estimated Funding: $14,100,000


Relevant Nonprofit Program Categories





Obtain Full Opportunity Text:
NIH Guide for Grants and Contracts

Additional Information of Eligibility:
Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions

Full Opportunity Web Address:


Contact:


Agency Email Description:


Agency Email:
vieda.hubbard@fda.hhs.gov

Date Posted:
2012-12-10

Application Due Date:
2014-10-16

Archive Date:
2014-11-15


301 Moved Permanently

Moved Permanently

The document has moved here.



More Federal Domestic Assistance Programs


Higher Education_Institutional Aid | Tobacco Regulation Awareness, Communication, and Education Program | Medicaid Infrastructure Grants To Support the Competitive Employment of People with Disabilities | Alternative or Innovative Treatment Technology Research, Demonstration, Training, and Hazardous Subs | Clean Fuels |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2024 Copyright Michael Saunders